Critical Diagnostics recently announced the results of the LURIC study of 1345 patients with stable coronary artery disease, established that, in a univariate analysis, patients with ST2 levels in the highest quartile exhibited a 2-fold increased risk of death. Results remained significant even in a fully adjusted model.
Can This Simple Test Predict Your Chances of Dying? If You Have Coronary Artery Disease, The Answer Is Yes, Say A Group of Renowned Scientists
Personal Genome Diagnostics Inc. (PGDx), a provider of advanced cancer genome analysis and testing services, reported that its proprietary technology was used in a major new study being published recently in the journal Science Translational Medicine. The study, “Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies,” assessed the utility of cell-free circulating tumor DNA (ctDNA) for cancer detection and monitoring across multiple patient populations and applications. The authors conclude that ctDNA is a broadly applicable, sensitive and specific biomarker that can be used for a variety of clinical and research purposes in patients with different types of cancer.
New research findings may soon help doctors personalize preterm birth prevention treatments by identifying which women at higher risk for preterm birth will be helped by progesterone injections.
As research unveils overlap in the biology — in addition to long-noted shared clinical symptoms — of Parkinson’s and Alzheimer’s diseases, three non-profit organizations are uniting to encourage further study into the similarities and differences between the two most common brain diseases, which affect tens of millions of people worldwide.
Ezose Sciences Receives Grant from Michael J. Fox Foundation to Use GlycanMap Technology in Parkinson’s Research
Ezose Sciences Inc. recently announced that it has received a grant from The Michael J. Fox Foundation for Parkinson’s Research to apply Ezose’s GlycanMap® technology to investigating the role of the sugars known as glycans in Parkinson’s disease.